CTLA4 and melanoma: Recent studies reported on a significantly longer overall survival in melanoma patients who were treated with the combination of anti‐PD‐1/anti‐CTLA‐4, or with anti‐PD‐1 alone, compared to those treated with anti‐CTLA‐4 alone.